拉呋替丁胶囊治疗胃溃疡患者的有效性与安全性探讨  

The efficacy and safety of ravetidine capsule in treating patients with gastric ulcer

作　　者：陈怡 CHEN Yi(Dept.of Pharmacy of Luoding People＇s Hospital,Louding 527200,China)

机构地区：[1]罗定市人民医院药学部,广东罗定527200

出　　处：《华夏医学》2018年第4期72-75,共4页Acta Medicinae Sinica

摘　　要：目的:探讨胃溃疡患者采用拉呋替丁治疗的效果及安全性。方法:将本院收治的100例胃溃疡患者随机分成观察组(n=50)与对照组(n=50)。对照组采用克拉霉素+甲硝唑+雷贝拉唑的治疗方案,观察组则采用克拉霉素+甲硝唑+拉呋替丁胶囊的治疗方案,观察两组患者的治疗效果、症状评分、不良反应发生情况。结果:观察组治疗总有效率为94.00%,明显高于对照组的74.00%(P<0.01);治疗后观察组症状总评分为(54.29±8.03)分,明显低于对照组的(61.15±9.97)分(P<0.01);观察组患者治疗期间不良反应发生率为8.00%,明显低于对照组的24.00%(P<0.01)。结论:采用拉呋替丁胶囊治疗胃溃疡可获得显著临床疗效,改善患者的症状,降低患者不良反应,值得在临床中推广应用。Objective： To investigate the efficacy and safety of ravetidine in the treatment of patients with gastric ulcer. Methods： 100 patients with gastric ulcer in our hospital were randomly divided into the experiment group（n = 50） and control group（n = 50）. Patients in the control group adopted clarithromycin,metronidazole and rabeprazole azole therapeutic regimen,while patients in the observation group were administered with metronidazole clarithromycin and lafutidine capsules treatment. Then,the therapeutic effects,symptom scores,adverse reactions occurred in both groups were evaluated. Results：The total effective rate of the experiment group was 94. 00%,significantly higher than 74. 00% in the control group（P〈0.01）; after treatment,the total scores of the experiment group were（54.29 ± 8.03）,significantly lower than that of the control group（61. 15 ± 9. 97）（P 〈0. 01）; the incidence of adverse reactions in the observation group was 8. 00%,obviously lower than 24. 00% in the control group（P〈 0.01）. Conclusion： The treatment of gastric ulcer with ravetidine capsule can obtain significant clinical curative effect,improve the symptoms and reduce the adverse reactions of patients,so it is worthy of clinical popularization and application.

关 键 词：胃溃疡 拉呋替丁 安全性 不良反应 

分 类 号：R574.1[医药卫生—消化系统]